Your browser doesn't support javascript.
loading
IT-Related Barriers and Facilitators to the Implementation of a New European eHealth Solution, the Digital Survivorship Passport (SurPass Version 2.0): Semistructured Digital Survey.
de Beijer, Ismay A E; van den Oever, Selina R; Charalambous, Eliana; Cangioli, Giorgio; Balaguer, Julia; Bardi, Edit; Alfes, Marie; Cañete Nieto, Adela; Correcher, Marisa; Pinto da Costa, Tiago; Degelsegger-Márquez, Alexander; Düster, Vanessa; Filbert, Anna-Liesa; Grabow, Desiree; Gredinger, Gerald; Gsell, Hannah; Haupt, Riccardo; van Helvoirt, Maria; Ladenstein, Ruth; Langer, Thorsten; Laschkolnig, Anja; Muraca, Monica; Pluijm, Saskia M F; Rascon, Jelena; Schreier, Günter; Tomásikova, Zuzana; Trauner, Florian; Trinkunas, Justas; Trunner, Kathrin; Uyttebroeck, Anne; Kremer, Leontien C M; van der Pal, Helena J H; Chronaki, Catherine.
Afiliación
  • de Beijer IAE; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • van den Oever SR; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Charalambous E; Health Level Seven Europe, Brussels, Belgium.
  • Cangioli G; Venizeleio General Hospital of Heraklion, Heraklion, Greece.
  • Balaguer J; Health Level Seven Europe, Brussels, Belgium.
  • Bardi E; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Alfes M; St Anna Children's Hospital, Vienna, Austria.
  • Cañete Nieto A; Department of Paediatrics and Adolescent Medicine, Kepler University Hospital, Johannes Kepler University Linz, Linz, Austria.
  • Correcher M; Childhood Cancer International Europe, Vienna, Austria.
  • Pinto da Costa T; Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Degelsegger-Márquez A; Instituto Investigación Sanitaria La Fe, Valencia, Spain.
  • Düster V; Childhood Cancer International Europe, Vienna, Austria.
  • Filbert AL; Gesundheit Österreich GmbH, Vienna, Austria.
  • Grabow D; Department of Studies and Statistics for Integrated Research and Projects, St Anna Children's Cancer Research Institute, Vienna, Austria.
  • Gredinger G; Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Gsell H; Division of Childhood Cancer Epidemiology, German Childhood Cancer Registry, Institute of Medical Biostatistics, Epidemiology and Informatics, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
  • Haupt R; Gesundheit Österreich GmbH, Vienna, Austria.
  • van Helvoirt M; Childhood Cancer International Europe, Vienna, Austria.
  • Ladenstein R; Diagnosi, Osservazione, Prevenzione dopo trattamento Oncologico Clinic, Department of Hematology/Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, Genova, Italy.
  • Langer T; University Hospitals Leuven, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Laschkolnig A; St Anna Children's Hospital, Vienna, Austria.
  • Muraca M; Department of Studies and Statistics for Integrated Research and Projects, St Anna Children's Cancer Research Institute, Vienna, Austria.
  • Pluijm SMF; Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
  • Rascon J; Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
  • Schreier G; Gesundheit Österreich GmbH, Vienna, Austria.
  • Tomásikova Z; Diagnosi, Osservazione, Prevenzione dopo trattamento Oncologico Clinic, Department of Hematology/Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Istituto Giannina Gaslini, Genova, Italy.
  • Trauner F; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Trinkunas J; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
  • Trunner K; Clinics for Children's Diseases, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
  • Uyttebroeck A; Center for Health and Bioresources, Austrian Institute of Technology, Graz, Austria.
  • Kremer LCM; Childhood Cancer International Europe, Vienna, Austria.
  • van der Pal HJH; Gesundheit Österreich GmbH, Vienna, Austria.
  • Chronaki C; Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania.
J Med Internet Res ; 26: e49910, 2024 05 02.
Article en En | MEDLINE | ID: mdl-38696248
ABSTRACT

BACKGROUND:

To overcome knowledge gaps and optimize long-term follow-up (LTFU) care for childhood cancer survivors, the concept of the Survivorship Passport (SurPass) has been invented. Within the European PanCareSurPass project, the semiautomated and interoperable SurPass (version 2.0) will be optimized, implemented, and evaluated at 6 LTFU care centers representing 6 European countries and 3 distinct health system scenarios (1) national electronic health information systems (EHISs) in Austria and Lithuania, (2) regional or local EHISs in Italy and Spain, and (3) cancer registries or hospital-based EHISs in Belgium and Germany.

OBJECTIVE:

We aimed to identify and describe barriers and facilitators for SurPass (version 2.0) implementation concerning semiautomation of data input, interoperability, data protection, privacy, and cybersecurity.

METHODS:

IT specialists from the 6 LTFU care centers participated in a semistructured digital survey focusing on IT-related barriers and facilitators to SurPass (version 2.0) implementation. We used the fit-viability model to assess the compatibility and feasibility of integrating SurPass into existing EHISs.

RESULTS:

In total, 13/20 (65%) invited IT specialists participated. The main barriers and facilitators in all 3 health system scenarios related to semiautomated data input and interoperability included unaligned EHIS infrastructure and the use of interoperability frameworks and international coding systems. The main barriers and facilitators related to data protection or privacy and cybersecurity included pseudonymization of personal health data and data retention. According to the fit-viability model, the first health system scenario provides the best fit for SurPass implementation, followed by the second and third scenarios.

CONCLUSIONS:

This study provides essential insights into the information and IT-related influencing factors that need to be considered when implementing the SurPass (version 2.0) in clinical practice. We recommend the adoption of Health Level Seven Fast Healthcare Interoperability Resources and data security measures such as encryption, pseudonymization, and multifactor authentication to protect personal health data where applicable. In sum, this study offers practical insights into integrating digital health solutions into existing EHISs.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Telemedicina Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Med Internet Res Asunto de la revista: INFORMATICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Telemedicina Límite: Humans País/Región como asunto: Europa Idioma: En Revista: J Med Internet Res Asunto de la revista: INFORMATICA MEDICA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos